Related Experiment Video

Updated: Mar 29, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development

Alberto Ocana1, Atanasio Pandiella

  • 1Cancer Research Center, CSIC-University of Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.

Current Cancer Drug Targets
|December 10, 2015
PubMed

Insights

Novel drug combinations leveraging synthetic lethality and collateral lethality can accelerate cancer drug development. This approach enhances efficacy in specific tumors while minimizing toxicity and aids in designing early clinical studies.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Preclinical evaluation of drug combinations presents significant challenges.
  • Synthetic lethality and collateral lethality are emerging concepts impacting drug development strategies.

Purpose of the Study:

  • To review the impact of synthetic lethality and collateral lethality on drug combination evaluation and clinical development.
  • To explore novel drug combinations, including those with immunologic agents.
  • To discuss the implications for early clinical study design.

Main Methods:

  • Review of the concept of synthetic lethality and its application in drug combination studies.
  • Analysis of novel combination strategies, including immunotherapy and agents targeting cancer cells.
  • Discussion of collateral lethality as a method to identify synergistic drug interactions.

Main Results:

  • Synthetic lethality and collateral lethality offer a framework to identify synergistic drug combinations.
  • Targeted combinations can enhance efficacy in tumors with specific molecular alterations and reduce toxicity to normal tissues.
  • Combining immunotherapy with targeted agents may offer non-overlapping toxicities and improved therapeutic outcomes.

Conclusions:

  • Identifying synthetic and collateral lethality interactions through novel drug combinations can accelerate the drug development pipeline.
  • This approach holds promise for developing effective and less toxic cancer therapies.
  • The findings have implications for the strategic design of early-phase clinical trials.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.2K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.0K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
330